Cite
HARVARD Citation
Morschhauser, F. et al. (n.d.). INTERIM UPDATE FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA. Hematological oncology. pp. 154-156. [Online].